Additional file 6: Table S2. The association of ORR and non-ORR, DCR and non-DCR with the status of five cocurrence driver gens in the patients with EGFR-mutation, respectively.

Figshare2024-02-28 更新30

DDX3X Induces Primary EGFR-TKI Resistance Based on Intratumor Heterogeneity in Lung Cancer Cells Harboring EGFR-Activating Mutations - Figure 3

EGFR-TKI耐药性

癌细胞实验

A. A total of 5×104 tumor cells were seeded in 24-well plates on day 0. Twenty-four hours after seeding, erlotinib or vehicle was added at the indicated concentrations. Numbers of live and dead cells

NIAID Data Ecosystem20

Next generation sequencing facilitates quantitative analysis of MTAC-P (EGFR-TKI resistant cell line derived from PC9) with and without BCAT1 knockdown.

EGFR-TKI耐药性

BCAT1

The goals of this study are to compare the different transcriptome signiture between MTAC-P cells with and without BCAT1 knockdown with NGS-derived retinal transcriptome profiling (RNA-seq). Overall d

NIAID Data Ecosystem50

Dataset from Phase I/II Open Label Trial of Continuous Once Daily Oral Treatment With BIBW 2992 - Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib.

非小细胞肺癌治疗

EGFR-TKI耐药性

The objective of the Phase I step is to estimate the MTD at a dose level up to 50 mg/day (i.e., overseas recommended Phase II dose) in patients with advanced NSCLC and to determine the recommended dos

NIAID Data Ecosystem30

Supplementary Table S2 from ER Stress Signaling Promotes the Survival of Cancer “Persister Cells” Tolerant to EGFR Tyrosine Kinase Inhibitors

资源简介：

相关数据集